Tyme Announces Positive Efficacy Data for SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium
40 percent of evaluable patients achieved survival of more than 12 months, 30 percent achieved a complete or partial tumor response All patients improved or maintained quality of life measures and pain scores SAN FRANCISCO, Jan. 19, 2018 (GLOBE NEWSWIRE) …